NeuroOne has grown into its technology over the past three years.
The company’s most recent announcement is the 510(k) submission for its new OneRF ablation system. With a radiofrequency generator, OneRF...
Minute Insight: NeuroOne Moves Forward With Brain Electrode 510(k) Submission
The company has submitted a 510(k) request for its OneRF Ablation System, which will repurpose previously implanted electrodes into a tool for brain tissue removal.
More from Neurology
• By
The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.
• By
Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.
• By
In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.
• By
Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.
More from Device Area
• By
Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.
• By
Ultrahuman seeks to “create an environment that aligns with our bodies" by linking environmental parameters collected by Ultrahuman Home to health physiology, measured by the Ultrahuman Ring Air.
• By
While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.